Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines

Experimental Cell Research

Volumn 316, Issue 7, 2010, Pages 1109-1118

  Chen, Chien Liang ^a,b   Chou, Kang Ju ^a,b   Lee, Po Tsang ^a,b   Chen, Ying Shou ^a   Chang, Tsu Yuan ^a   Hsu, Chih Yang ^a   Huang, Wei Chieh ^a   Chung, Hsiao Min ^a,b   Fang, Hua Chang ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Epithelial mesenchymal transition; Erythropoietin; Tumor growth factor 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RECOMBINANT ERYTHROPOIETIN; SMAD PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; INHIBITION KINETICS; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SWINE; WESTERN BLOTTING;

SUIDAE;

EID: 77950621871     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.02.022     Document Type: Article

References (28)

1. Bohle A., Muller G.A., Wehrmann M., Xiao J.C. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int. 1996, 54:S2-S9.
2. Hay E.D. An overview of epithelio-mesenchymal transformation. Acta Anat. 1995, 154:8-20.
3. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003, 112:1776-1784.
4. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
5. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 2002, 110:341-350.
6. Okada H., Danoff T.M., Kalluri R., Neilson E.G. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. Renal. Physiol. 1997, 273:F563-F574.
7. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 2004, 15:1-12.
8. Rhyu D.Y., Yang Y., Ha H., Lee G.T., Song J.S., Uh S.T., Lee H.B. Role of reactive oxygen species in TGF-1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J. Am. Soc. Nephrol. 2005, 16:667-675.
9. Dooley S., Hamzavi J., Breitkopf K., Wiercinska E., Said H.M., Lorenzen J., Ten Dijke P., Gressner A.M. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003, 125:178-191.
10. Krantz S. Erythropoietin. Blood 1991, 77:419-434.
11. Sakanaka M., Wen T.C., Matsuda S., Masuda S., Morishita E., Nagao M., Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4635-4640.
12. Patel N.S., Sharples E.J., Cuzzocrea S., Chatterjee P.K., Britti D., Yaqoob M.M., Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004, 66:983-989.
13. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., Kieswich J., Allen D., Harwood S., Raftery M., Thiemermann C., Yaqoob M.M. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemiareperfusion. J. Am. Soc. Nephrol. 2004, 15:2115-2124.
14. Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M., Tsukamoto O., Okada K., Koyama H., Komamura K., Takashima S., Shinozaki Y., Mori H., Shiraga M., Kitakaze M., Hori M. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 2006, 48:176-184.
15. Park S.H., Choi M.J., Song I.K., Choi S.Y., Nam J.O., Kim C.D., Lee B.H., Park R.W., Park K.M., Kim Y.J., Kim I.S., Kwon T.H., Kim Y.L. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 2007, 18:1497-1507.
16. Wang Y.N., Chen Y.J., Chang W.C. Activation of extracellular signal-regulated kinase signaling by epidermal growth factor mediates c-Jun activation and p300 recruitment in keratin 16 gene expression. Mol. Pharmacol. 2006, 69:85-98.
17. Westenfelder C., Biddle D.L., Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999, 55:808-820.
18. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., Kirsch T., de Groot K., Laudeley R., Niemczyk E., Güler F., Menne J., Haller H., Fliser D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004, 110:1006-1012.
19. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., Schwab S.J., Goodkin D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998, 339:584-590.
20. Garcia D.L., Anderson S., Rennke H.G., Brenner B.M. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6142-6146.
21. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1:169-178.
22. Massague J., Chen Y.G. Controlling TGF-beta signaling. Genes Dev. 2000, 14:627-644.
23. Wrana J.L. Regulation of Smad activity. Cell 2000, 100:189-192.
24. Wotton D., Massague J. Smad transcriptional corepressors in TGF beta family signaling. Curr. Top. Microbiol. Immunol. 2001, 254:145-164.
25. Li J.H., Zhu H.J., Huang X.R., Lai K.N., Johnson R.J., Lan H.Y. Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J. Am. Soc. Nephrol. 2002, 13:1464-1472.
26. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGF beta/Smad signaling by oncogenic Ras. Genes Dev. 1999, 13:804-816.
27. Yang J., Dai C., Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am. J. Pathol. 2003, 163:621-632.
28. Coleman T.R., Westenfelder C., Tögel F.E., Yang Y., Hu Z., Swenson L., Leuvenink H.G., Ploeg R.J., d'Uscio L.V., Katusic Z.S., Ghezzi P., Zanetti A., Kaushansky K., Fox N.E., Cerami A., Brines M. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5965-5970.